| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001049337 |
| P356 | DOI | 10.1186/1476-511X-9-42 |
| P932 | PMC publication ID | 2873482 |
| P698 | PubMed publication ID | 20426802 |
| P50 | author | Stig B.S. Bengmark | Q54250285 |
| P2093 | author name string | Qing Liu | |
| Shen Qu | |||
| P2860 | cites work | Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis | Q73735584 |
| Inflammation and insulin resistance | Q22241893 | ||
| Insulin degradation: progress and potential | Q28287093 | ||
| Prevention of fat-induced insulin resistance by salicylate | Q28345600 | ||
| FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice | Q28507512 | ||
| Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. | Q51580928 | ||
| Hepatic Removal of Insulin in Normal Man: Dose Response to Endogenous Insulin Secretion* | Q51646799 | ||
| Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects. | Q51651113 | ||
| Differences in the hepatic and renal extraction of insulin and glucagon in the dog: evidence for saturability of insulin metabolism. | Q51855439 | ||
| Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. | Q53555710 | ||
| Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. | Q54511436 | ||
| MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. | Q55042948 | ||
| Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance | Q56742768 | ||
| Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man | Q66960336 | ||
| Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation | Q73715097 | ||
| Cellular mechanism of insulin resistance: potential links with inflammation | Q75220930 | ||
| Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples | Q79633397 | ||
| Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary | Q80470858 | ||
| Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease | Q80565685 | ||
| Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis | Q81301916 | ||
| Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis | Q82294435 | ||
| Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis | Q82677113 | ||
| Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey | Q94705856 | ||
| Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease | Q28571421 | ||
| Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes | Q28646399 | ||
| TLR4 links innate immunity and fatty acid-induced insulin resistance | Q29617577 | ||
| Innate immunity | Q29618949 | ||
| Interleukin-1-receptor antagonist in type 2 diabetes mellitus | Q29619001 | ||
| Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB | Q29619314 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Pathogenesis of non-alcoholic fatty liver disease. | Q33606303 | ||
| Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance | Q34137882 | ||
| Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism | Q34361926 | ||
| Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines | Q34467338 | ||
| Effect of Intraduodenal Glucose Administration on Hepatic Extraction of Insulin in the Anesthetized Dog | Q34509786 | ||
| Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation | Q34512108 | ||
| A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
| Biochemical and physiological function of stearoyl-CoA desaturase | Q34898764 | ||
| A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. | Q35222087 | ||
| Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models | Q35625539 | ||
| FoxOs at the crossroads of cellular metabolism, differentiation, and transformation | Q35770614 | ||
| Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease | Q36034875 | ||
| Innate immunity in the liver | Q36036373 | ||
| FoxO proteins in insulin action and metabolism | Q36110215 | ||
| Recent concepts in non-alcoholic fatty liver disease | Q36234172 | ||
| Role of inflammation in nonalcoholic steatohepatitis | Q36284149 | ||
| Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes | Q36321560 | ||
| Nonalcoholic fatty liver disease: from steatosis to cirrhosis | Q36382279 | ||
| Natural history of nonalcoholic steatohepatitis | Q36422700 | ||
| Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose | Q36462545 | ||
| The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. | Q36472264 | ||
| Non alcoholic fatty liver disease: a clinical approach and review | Q36475998 | ||
| Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice | Q36479005 | ||
| Nonalcoholic steatohepatitis: pathologic features and differential diagnosis | Q36580461 | ||
| Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease | Q36593429 | ||
| Central insulin action regulates peripheral glucose and fat metabolism in mice | Q36597490 | ||
| Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis | Q36669223 | ||
| 1. Fatty liver and non-alcoholic steatohepatitis | Q36707085 | ||
| Fatty liver and insulin resistance: not always linked | Q36742407 | ||
| siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle | Q36807616 | ||
| Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. | Q36972844 | ||
| Pathology of nonalcoholic fatty liver disease | Q36977000 | ||
| Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver | Q37023053 | ||
| Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment | Q37051418 | ||
| Impact of non-alcoholic fatty liver disease on accelerated metabolic complications | Q37141242 | ||
| FoxO1 integrates insulin signaling to VLDL production | Q37148966 | ||
| Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism | Q37149810 | ||
| Hepatic triglyceride synthesis and nonalcoholic fatty liver disease | Q37156321 | ||
| Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome | Q37226355 | ||
| Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis | Q37276342 | ||
| Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. | Q37310292 | ||
| The role of the lipogenic pathway in the development of hepatic steatosis. | Q37386081 | ||
| New insights into the pathophysiology of nonalcoholic fatty liver disease. | Q37452721 | ||
| Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis | Q37485124 | ||
| Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems | Q37499907 | ||
| Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease | Q38358419 | ||
| Extraction of Insulin by Liver | Q39927378 | ||
| C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations | Q40177948 | ||
| Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways | Q40264330 | ||
| Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes | Q40266335 | ||
| Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. | Q40301333 | ||
| A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. | Q40464366 | ||
| Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes | Q40555990 | ||
| Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. | Q40589626 | ||
| Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. | Q42462295 | ||
| Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase | Q42563412 | ||
| Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study | Q43654161 | ||
| Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. | Q44190785 | ||
| Neutralization of tumor necrosis factor-alpha reverses insulin resistance in skeletal muscle but not adipose tissue | Q44948837 | ||
| Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis | Q45077756 | ||
| NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study | Q46084938 | ||
| Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)? | Q46368206 | ||
| Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans | Q46513257 | ||
| Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Q46533800 | ||
| Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes | Q46599718 | ||
| JNK1 but not JNK2 promotes the development of steatohepatitis in mice | Q46865809 | ||
| Effect of liver fat on insulin clearance | Q46982115 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 42 | |
| P577 | publication date | 2010-04-28 | |
| P1433 | published in | Lipids in Health and Disease | Q15756695 |
| P1476 | title | The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). | |
| P478 | volume | 9 |
| Q55530834 | A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. |
| Q34779049 | Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. |
| Q36941874 | Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice |
| Q42756198 | Association between Nicotinamide Phosphoribosyltransferase and de novo Lipogenesis in Nonalcoholic Fatty Liver Disease. |
| Q35782502 | Association between serum alanine aminotransferase level and obesity indices in Korean adolescents |
| Q97524395 | Beneficial effects of Chinese herbs in the treatment of fatty liver diseases |
| Q37443840 | Bibliometric analysis of top 100 cited articles in nonalcoholic fatty liver disease research. |
| Q33591710 | Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents |
| Q92204214 | CHP1 Regulates Compartmentalized Glycerolipid Synthesis by Activating GPAT4 |
| Q38327569 | Carnosic acid (CA) prevents lipid accumulation in hepatocytes through the EGFR/MAPK pathway |
| Q45392774 | Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance |
| Q44222140 | Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population |
| Q47145626 | Curcumin enhances liver SIRT3 expression in the rat model of cirrhosis. |
| Q51082561 | Deficiency of CKIP-1 aggravates high-fat diet-induced fatty liver in mice. |
| Q40987059 | Dietary restriction, caloric value and the accumulation of hepatic fat. |
| Q89529434 | Effects of 1,25-dihydroxyvitamin D3 on the Inflammatory Responses of Stromal Vascular Cells and Adipocytes from Lean and Obese Mice |
| Q91727269 | Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models |
| Q90157746 | Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial |
| Q58740690 | Evaluation of two-point Dixon water-fat separation for liver specific contrast-enhanced assessment of liver maximum capacity |
| Q44583057 | Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. |
| Q41944168 | GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease |
| Q38234416 | GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease |
| Q36369189 | Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review |
| Q92059925 | Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease |
| Q35905331 | Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance |
| Q87610149 | Identification and validation co-differentially expressed genes with NAFLD and insulin resistance |
| Q86048539 | Impaired PI3 K Akt expression in liver and skeletal muscle of ovariectomized rats |
| Q93004201 | Improvement of Nonalcoholic Fatty Liver Disease Reduces the Risk of Type 2 Diabetes Mellitus |
| Q93355678 | Is non-alcoholic fatty liver disease a reflection of what we eat or simply how much we eat? |
| Q91792524 | MTP genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients |
| Q50115683 | Metabolic profiling of ob/ob mouse fatty liver using HR-MAS 1H-NMR combined with gene expression analysis reveals alterations in betaine metabolism and the transsulfuration pathway |
| Q34992352 | Metabolic syndrome and gastro-esophageal reflux: A link towards a growing interest in developed countries |
| Q26738646 | Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease |
| Q92714639 | N,N'-diacetylcystine ameliorates inflammation in experimental non-alcoholic steatohepatitis by regulating nuclear transcription factor kappa B activation |
| Q93379612 | Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden |
| Q90750222 | Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis |
| Q35380845 | Potential epigenetic mechanism in non-alcoholic Fatty liver disease |
| Q90284167 | Relationship between Muscle Mass/Strength and Hepatic Fat Content in Post-Menopausal Women |
| Q33690123 | Repeated sense of hunger leads to the development of visceral obesity and metabolic syndrome in a mouse model |
| Q24610857 | Role of nuclear receptor corepressor RIP140 in metabolic syndrome |
| Q38820176 | Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress |
| Q39973908 | Structure and age-dependent development of the turkey liver: a comparative study of a highly selected meat-type and a wild-type turkey line. |
| Q27497351 | Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease |
| Q33653828 | The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease |
| Q92151798 | The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism |
| Q50673306 | The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation. |
| Q37867697 | The mechanistic basis for the induction of hepatic steatosis by xenobiotics |
| Q43094757 | The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice. |
| Q38819558 | Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases. |
| Q36616784 | What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? |
Search more.